CAPPED BONUSZERTIFIKAT - BIONTECH ADR Stock

Certificat

DE000PC1TR97

Real-time Bid/Ask 13:00:24 2024-06-05 EDT
94.97 EUR / 95.32 EUR +2.24% Intraday chart for CAPPED BONUSZERTIFIKAT - BIONTECH ADR
Current month-1.27%
1 month+6.78%
Date Price Change
24-06-05 95.05 +2.14%
24-06-04 93.06 -2.26%
24-06-03 95.21 +1.01%
24-05-31 94.26 +1.21%
24-05-30 93.13 +5.70%

Delayed Quote Börse Stuttgart

Last update June 05, 2024 at 01:00 pm

More quotes

Static data

Product typeBonus- and Part-Guarantee-Certificates
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC1TR9
ISINDE000PC1TR97
Date issued 2023-12-13
Strike 150 $
Maturity 2025-12-19 (562 Days)
Parity 1 : 1
Emission price 84.13
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 97.33
Lowest since issue 76.89
Spread 0.35
Spread %0.37%

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
91.42 EUR
Average target price
103.1 EUR
Spread / Average Target
+12.78%
Consensus